Selinexor and Backbone Treatments of Multiple Myeloma Patients

ClinicalTrials.gov ID: NCT02343042

Public ClinicalTrials.gov record NCT02343042. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Study identification

NCT ID: NCT02343042
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Enrollment: 300 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Belantamab Mafodotin Drug
Bortezomib Drug
Carfilzomib Drug
Clarithromycin Drug
Daratumumab Drug
Dexamethasone Drug
Elotuzumab Drug
Ixazomib Drug
Lenalidomide Drug
Mezigdomide Drug
Pomalidomide Drug
Selinexor Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2015
Primary completion: Mar 31, 2027
Completion: Mar 31, 2027
Last update posted: May 3, 2026

2015 – 2027

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Banner MD Anderson Cancer Center	Gilbert	Arizona	85234	—
Jonnsson Comprehensive Cancer Center / University of Los Angeles	Los Angeles	California	0095	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
Hackensack University Medical Center - John Theurer Cancer Center	Hackensack	New Jersey	07601	—
Columbia University	New York	New York	10032	—
Weill Cornell Medicine	New York	New York	10065	—
Wilmot Cancer Center/ University of Rochester	Rochester	New York	—	—
University of North Carolina - Chapel Hill Comprehensive Cancer Center	Chapel Hill	North Carolina	27599	—
Duke Institute of Cancer/ Duke University	Durham	North Carolina	27710	—
Sarah Cannon- Tennessee Oncology Nashville	Nashville	Tennessee	37203	—
Fred Hutch Cancer Center	Seattle	Washington	98109	—
Swedish Cancer Institute	Seattle	Washington	98109	—
University of Wisconsin School of Medicine and Public Health	Madison	Wisconsin	53792	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02343042, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 3, 2026 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02343042 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →